EGFR and cancer: Vice versa, further studies need to evaluate the feasibility of using JAK-inhibitors to treat EGFR-inhibitor induced adverse events, as JAK-inhibitors are predicted to rather support cancer growth by blunting the activity of cytotoxic T-cells.